Sabby Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Sabby Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-174,900	Closed	-$738K	–	357
2016 Q2	$738K	Sell	174,900 -170,297	-49%	-$822K	0.04%	190
2016 Q1	$1.5M	Buy	+345,197	New	+$1.54M	0.08%	125
2015 Q3	–	Sell	-247,706	Closed	-$1.9M	–	418
2015 Q2	$1.85M	Sell	247,706 -371,694	-60%	-$2.25M	0.07%	170
2015 Q1	$3.7M	Buy	619,400 +555,401	+868%	+$3.5M	0.15%	99
2014 Q4	$484	Buy	+63,999	New	+$383K	0.02%	187
2014 Q3	–	Sell	-365,186	Closed	-$1.57M	–	316
2014 Q2	$1.57M	Sell	365,186 -152,608	-29%	-$583K	0.07%	119
2014 Q1	$2.12M	Buy	+517,794	New	+$2.65M	0.12%	101

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sabby Management's PGNX Position: Q3 2016 in Review

Sabby Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2016, closing a stake of 174,900 shares — an estimated $738K sold.

Sabby Management first reported a position in PGNX in Q1 2014 and held it in 7 quarters. The position peaked at $3.7M in Q1 2015. 115 funds tracked by Wall St. Rank hold PGNX as of Q3 2016.

Sabby Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
Sabby Management sold 174,900 Progenics Pharmaceuticals Inc shares in Q3 2016, an estimated $738K.
Sabby Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2014 and held it in 7 quarters.
Sabby Management's Progenics Pharmaceuticals Inc position peaked at $3.7M in Q1 2015.
115 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.